Targovax, along with SOTIO, has dosed the first patient in a Phase I/II clinical trial investigating the safety and immune activation of ONCOS-102 in combination with DCVAC/PCa for the treatment of men with advanced metastatic castration-resistant prostate cancer.
The patient has been dosed with ONCOS-102 at the Motol University Hospital in Prague, Czech Republic, by the trial’s principal investigator Dr Ladislav Jarolím.
Go deeper with GlobalData
Up to 15 patients are expected to be enrolled in the single-arm trial across various centres in the Czech Republic and the UK.
The trial’s primary goal is to examine the safety of DCVAC/PCa and ONCOS-102 combination primed with cyclophosphamide (CPO) in the advanced metastatic castration-resistant prostate cancer, which have progressed following initial therapy with either hormonal manipulation or chemotherapy.
Its secondary goals include the time to disease progression demonstrated by prostate-specific antigen (PSA) levels, as well as radiographic progression-free survival by radiographic evidence of disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, overall survival, and objective response rate.
Targovax CMO Magnus Jäderberg said: “Finding the right combination treatments is crucial to boost the response rate to immunotherapies, and in this particular trial we are testing the hypothesis of whether intratumoral delivery of ONCOS-102 and its transgene payload, GM-CSF, can provide a trafficking signal that enhances recruitment of the DCVAC dendritic cells to the prostate tumour site.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTargovax’s ONCOS-102 is the company’s lead adenovirus-based pipeline product, which is a purposefully engineered human serotype 5 adenovirus optimised to induce systemic anti-tumour T-cell responses in cancer patients.
DCVAC/PCa is developed by SOTIO and as an active cellular immunotherapy treatment for prostate cancer patients.
